| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Photochemotherapy | 25 | 2020 | 97 | 2.930 |
Why?
|
| Ultraviolet Therapy | 8 | 2018 | 15 | 1.480 |
Why?
|
| Psoriasis | 16 | 2018 | 240 | 1.370 |
Why?
|
| Aminolevulinic Acid | 14 | 2012 | 21 | 1.220 |
Why?
|
| Photosensitizing Agents | 14 | 2020 | 48 | 1.120 |
Why?
|
| Dermatologic Agents | 3 | 2018 | 71 | 1.060 |
Why?
|
| Protoporphyrins | 8 | 2006 | 19 | 0.800 |
Why?
|
| Methoxsalen | 12 | 2001 | 15 | 0.690 |
Why?
|
| Ultraviolet Rays | 15 | 2015 | 193 | 0.600 |
Why?
|
| PUVA Therapy | 15 | 1999 | 24 | 0.590 |
Why?
|
| Biological Products | 1 | 2018 | 143 | 0.560 |
Why?
|
| Photosensitivity Disorders | 8 | 1992 | 15 | 0.480 |
Why?
|
| Skin Diseases | 3 | 2010 | 166 | 0.480 |
Why?
|
| Receptors, Tumor Necrosis Factor | 1 | 2013 | 88 | 0.460 |
Why?
|
| Skin Neoplasms | 11 | 2017 | 546 | 0.440 |
Why?
|
| Keratinocytes | 4 | 2015 | 143 | 0.410 |
Why?
|
| Immunoglobulin G | 2 | 2013 | 456 | 0.400 |
Why?
|
| Porphyrins | 8 | 2012 | 39 | 0.390 |
Why?
|
| Laser Therapy | 3 | 2017 | 142 | 0.330 |
Why?
|
| Carcinoma, Basal Cell | 5 | 2017 | 54 | 0.330 |
Why?
|
| Cell Differentiation | 4 | 2020 | 1458 | 0.290 |
Why?
|
| Prostatic Neoplasms | 6 | 2006 | 1721 | 0.280 |
Why?
|
| Lasers, Gas | 2 | 2017 | 4 | 0.280 |
Why?
|
| Sebaceous Glands | 1 | 2006 | 28 | 0.280 |
Why?
|
| Cryotherapy | 2 | 2017 | 29 | 0.270 |
Why?
|
| Radiation-Sensitizing Agents | 4 | 2001 | 94 | 0.270 |
Why?
|
| Deferoxamine | 4 | 1995 | 18 | 0.250 |
Why?
|
| Vitiligo | 4 | 1988 | 15 | 0.240 |
Why?
|
| Vitamin D | 3 | 2020 | 261 | 0.220 |
Why?
|
| Humans | 63 | 2018 | 86645 | 0.210 |
Why?
|
| Receptors, Immunologic | 2 | 2000 | 135 | 0.200 |
Why?
|
| Tumor Cells, Cultured | 10 | 2002 | 1041 | 0.190 |
Why?
|
| Skin | 11 | 1999 | 554 | 0.190 |
Why?
|
| Khellin | 4 | 1988 | 4 | 0.190 |
Why?
|
| Erythema | 5 | 1999 | 27 | 0.180 |
Why?
|
| Hyperthermia, Induced | 1 | 2000 | 73 | 0.180 |
Why?
|
| Neoplasms, Experimental | 1 | 2000 | 269 | 0.160 |
Why?
|
| Keratosis, Actinic | 2 | 2015 | 11 | 0.160 |
Why?
|
| Male | 28 | 2018 | 40967 | 0.160 |
Why?
|
| Europe | 1 | 2018 | 309 | 0.160 |
Why?
|
| Aged, 80 and over | 5 | 2018 | 6509 | 0.150 |
Why?
|
| Neoadjuvant Therapy | 1 | 2020 | 318 | 0.150 |
Why?
|
| Aged | 14 | 2018 | 18415 | 0.150 |
Why?
|
| Dermatitis, Photoallergic | 2 | 1995 | 2 | 0.150 |
Why?
|
| Lymphomatoid Granulomatosis | 2 | 1987 | 5 | 0.150 |
Why?
|
| Physicians, Primary Care | 1 | 2018 | 104 | 0.150 |
Why?
|
| Combined Modality Therapy | 6 | 2013 | 1686 | 0.150 |
Why?
|
| Adolescent | 6 | 2018 | 8982 | 0.140 |
Why?
|
| Disease Management | 1 | 2018 | 327 | 0.140 |
Why?
|
| DNA-Binding Proteins | 1 | 2001 | 1208 | 0.130 |
Why?
|
| Primary Health Care | 1 | 2018 | 339 | 0.130 |
Why?
|
| Middle Aged | 15 | 2018 | 25028 | 0.130 |
Why?
|
| Facial Dermatoses | 1 | 2014 | 13 | 0.120 |
Why?
|
| Scalp Dermatoses | 1 | 2014 | 10 | 0.120 |
Why?
|
| Young Adult | 2 | 2018 | 5976 | 0.120 |
Why?
|
| Lymphoma, T-Cell, Cutaneous | 1 | 1994 | 12 | 0.120 |
Why?
|
| Baths | 4 | 1994 | 8 | 0.120 |
Why?
|
| Transcription Factors | 1 | 2001 | 1565 | 0.120 |
Why?
|
| Female | 21 | 2018 | 44534 | 0.120 |
Why?
|
| Etanercept | 1 | 2013 | 32 | 0.120 |
Why?
|
| Adult | 15 | 2018 | 25648 | 0.110 |
Why?
|
| Gene Expression Regulation | 1 | 2001 | 1920 | 0.110 |
Why?
|
| Severity of Illness Index | 1 | 2018 | 1801 | 0.110 |
Why?
|
| Carcinoma, Squamous Cell | 5 | 2015 | 1076 | 0.110 |
Why?
|
| Netherton Syndrome | 1 | 2012 | 2 | 0.110 |
Why?
|
| Proto-Oncogene Proteins B-raf | 1 | 2013 | 138 | 0.110 |
Why?
|
| Cutis Laxa | 1 | 1992 | 4 | 0.110 |
Why?
|
| Methotrexate | 4 | 2012 | 249 | 0.110 |
Why?
|
| Elastic Tissue | 1 | 1992 | 18 | 0.110 |
Why?
|
| Drug Administration Schedule | 2 | 2013 | 916 | 0.100 |
Why?
|
| Melanoma | 3 | 2013 | 459 | 0.100 |
Why?
|
| Skin Aging | 1 | 1992 | 28 | 0.100 |
Why?
|
| Cohort Studies | 1 | 2018 | 2767 | 0.100 |
Why?
|
| Phagocytosis | 1 | 1992 | 85 | 0.100 |
Why?
|
| Indoles | 1 | 2013 | 318 | 0.100 |
Why?
|
| Matrix Metalloproteinase 9 | 2 | 2003 | 78 | 0.100 |
Why?
|
| Prospective Studies | 3 | 2017 | 4213 | 0.100 |
Why?
|
| Recurrence | 2 | 2013 | 1139 | 0.100 |
Why?
|
| Sulfonamides | 1 | 2013 | 300 | 0.100 |
Why?
|
| Superoxide Dismutase | 2 | 1999 | 177 | 0.100 |
Why?
|
| Riboflavin | 1 | 1990 | 6 | 0.100 |
Why?
|
| Neoplasms, Second Primary | 1 | 2013 | 252 | 0.100 |
Why?
|
| Loose Anagen Hair Syndrome | 1 | 2010 | 5 | 0.090 |
Why?
|
| Hair | 1 | 2010 | 56 | 0.090 |
Why?
|
| Rats | 8 | 2003 | 3990 | 0.090 |
Why?
|
| Animals | 19 | 2006 | 26582 | 0.090 |
Why?
|
| Ovarian Neoplasms | 3 | 2001 | 744 | 0.090 |
Why?
|
| Leiomyoma | 1 | 2013 | 191 | 0.090 |
Why?
|
| Light | 4 | 2006 | 289 | 0.090 |
Why?
|
| DNA | 4 | 1993 | 1294 | 0.090 |
Why?
|
| Sulfadoxine | 1 | 1989 | 2 | 0.090 |
Why?
|
| Sulfanilamides | 1 | 1989 | 5 | 0.090 |
Why?
|
| Pyrimethamine | 1 | 1989 | 21 | 0.090 |
Why?
|
| Chloroquine | 1 | 1989 | 12 | 0.090 |
Why?
|
| Mice | 9 | 2006 | 11352 | 0.090 |
Why?
|
| Lipid Peroxidation | 1 | 2009 | 44 | 0.080 |
Why?
|
| Malaria | 1 | 1989 | 23 | 0.080 |
Why?
|
| Stevens-Johnson Syndrome | 1 | 1989 | 22 | 0.080 |
Why?
|
| Antimalarials | 1 | 1989 | 20 | 0.080 |
Why?
|
| Cell Line | 2 | 2006 | 2468 | 0.080 |
Why?
|
| Complement Activation | 1 | 2009 | 81 | 0.080 |
Why?
|
| Niacinamide | 1 | 1988 | 116 | 0.080 |
Why?
|
| Transcriptional Activation | 1 | 2009 | 280 | 0.080 |
Why?
|
| Microscopy, Confocal | 2 | 2006 | 268 | 0.080 |
Why?
|
| Metribolone | 2 | 2006 | 5 | 0.070 |
Why?
|
| Macrophages | 4 | 2001 | 554 | 0.070 |
Why?
|
| Treatment Outcome | 3 | 2014 | 7993 | 0.070 |
Why?
|
| Eyelid Diseases | 1 | 1986 | 6 | 0.070 |
Why?
|
| Microscopy, Fluorescence | 2 | 2006 | 425 | 0.070 |
Why?
|
| Matrix Metalloproteinase Inhibitors | 2 | 2003 | 14 | 0.070 |
Why?
|
| Dose-Response Relationship, Radiation | 7 | 2001 | 188 | 0.070 |
Why?
|
| Mitochondria | 3 | 2006 | 535 | 0.070 |
Why?
|
| RNA, Messenger | 3 | 2001 | 1981 | 0.070 |
Why?
|
| Sunlight | 3 | 2015 | 26 | 0.070 |
Why?
|
| Mice, Nude | 3 | 2001 | 790 | 0.070 |
Why?
|
| Transcription, Genetic | 2 | 2001 | 1135 | 0.060 |
Why?
|
| Apoptosis | 2 | 2009 | 1683 | 0.060 |
Why?
|
| Cytokines | 1 | 2009 | 776 | 0.060 |
Why?
|
| Fluorescent Dyes | 1 | 2006 | 242 | 0.060 |
Why?
|
| Administration, Oral | 5 | 2002 | 684 | 0.060 |
Why?
|
| Euglena gracilis | 2 | 1994 | 8 | 0.060 |
Why?
|
| Chlorophyllides | 2 | 2001 | 5 | 0.060 |
Why?
|
| Hydro-Lyases | 2 | 1994 | 6 | 0.060 |
Why?
|
| Alcohol Oxidoreductases | 2 | 1994 | 17 | 0.060 |
Why?
|
| Alkyl and Aryl Transferases | 2 | 1994 | 15 | 0.060 |
Why?
|
| Lyases | 2 | 1994 | 11 | 0.060 |
Why?
|
| Multienzyme Complexes | 2 | 1994 | 64 | 0.060 |
Why?
|
| Phosphotransferases (Alcohol Group Acceptor) | 2 | 1994 | 80 | 0.060 |
Why?
|
| Piperazines | 2 | 2003 | 272 | 0.060 |
Why?
|
| Testosterone Congeners | 1 | 2002 | 2 | 0.060 |
Why?
|
| Pyrimidines | 2 | 2003 | 370 | 0.050 |
Why?
|
| Cell Division | 4 | 2002 | 696 | 0.050 |
Why?
|
| Enzyme Inhibitors | 2 | 2003 | 639 | 0.050 |
Why?
|
| Tretinoin | 1 | 2002 | 126 | 0.050 |
Why?
|
| Uterine Cervical Dysplasia | 1 | 2002 | 27 | 0.050 |
Why?
|
| beta-Galactosidase | 1 | 2001 | 71 | 0.050 |
Why?
|
| Cells, Cultured | 4 | 2001 | 2818 | 0.050 |
Why?
|
| Mice, Inbred Strains | 1 | 2001 | 307 | 0.050 |
Why?
|
| Deuteroporphyrins | 1 | 2001 | 1 | 0.050 |
Why?
|
| Organotin Compounds | 1 | 2001 | 1 | 0.050 |
Why?
|
| Mutagenesis, Insertional | 1 | 2001 | 111 | 0.050 |
Why?
|
| Receptors, Scavenger | 1 | 2000 | 3 | 0.050 |
Why?
|
| Scavenger Receptors, Class A | 1 | 2000 | 5 | 0.050 |
Why?
|
| Cell Survival | 3 | 2006 | 969 | 0.050 |
Why?
|
| Biopsy | 3 | 1992 | 1163 | 0.050 |
Why?
|
| Flow Cytometry | 1 | 2002 | 679 | 0.050 |
Why?
|
| Serum Albumin, Bovine | 1 | 2000 | 45 | 0.050 |
Why?
|
| DNA Primers | 1 | 2001 | 543 | 0.050 |
Why?
|
| Forkhead Transcription Factors | 1 | 2001 | 166 | 0.050 |
Why?
|
| Phenylalanine | 1 | 2000 | 37 | 0.050 |
Why?
|
| Hematoporphyrin Derivative | 2 | 1996 | 3 | 0.050 |
Why?
|
| Thiophenes | 1 | 2000 | 48 | 0.050 |
Why?
|
| Antibodies, Antinuclear | 2 | 1992 | 83 | 0.050 |
Why?
|
| Drug Carriers | 1 | 2000 | 81 | 0.050 |
Why?
|
| DNA Replication | 2 | 1993 | 164 | 0.040 |
Why?
|
| Follow-Up Studies | 6 | 1996 | 3640 | 0.040 |
Why?
|
| Integrin beta1 | 1 | 1999 | 33 | 0.040 |
Why?
|
| Impetigo | 1 | 1999 | 1 | 0.040 |
Why?
|
| Bowen's Disease | 2 | 1996 | 9 | 0.040 |
Why?
|
| Neoplasms | 2 | 2012 | 2898 | 0.040 |
Why?
|
| Dermatitis Herpetiformis | 1 | 1999 | 9 | 0.040 |
Why?
|
| Polyethylene Glycols | 1 | 2001 | 363 | 0.040 |
Why?
|
| Extracellular Matrix Proteins | 1 | 1999 | 123 | 0.040 |
Why?
|
| Time Factors | 5 | 2002 | 5210 | 0.040 |
Why?
|
| Porphobilinogen Synthase | 1 | 1998 | 4 | 0.040 |
Why?
|
| Phototherapy | 1 | 2018 | 35 | 0.040 |
Why?
|
| Heme | 1 | 1998 | 63 | 0.040 |
Why?
|
| Promoter Regions, Genetic | 1 | 2001 | 937 | 0.040 |
Why?
|
| Temperature | 1 | 1999 | 396 | 0.040 |
Why?
|
| Signal Transduction | 1 | 2009 | 3241 | 0.040 |
Why?
|
| Biological Therapy | 1 | 2018 | 45 | 0.040 |
Why?
|
| Transferases | 2 | 1994 | 24 | 0.040 |
Why?
|
| Hordeum | 1 | 1997 | 10 | 0.040 |
Why?
|
| Plant Growth Regulators | 1 | 1997 | 10 | 0.040 |
Why?
|
| Mice, Transgenic | 1 | 2001 | 1540 | 0.040 |
Why?
|
| Cyclopentanes | 1 | 1997 | 27 | 0.040 |
Why?
|
| Torso | 1 | 2017 | 12 | 0.040 |
Why?
|
| Gene Expression Regulation, Plant | 1 | 1997 | 91 | 0.040 |
Why?
|
| Radiotherapy Dosage | 2 | 1999 | 468 | 0.040 |
Why?
|
| Genes, Plant | 2 | 1997 | 99 | 0.040 |
Why?
|
| Administration, Cutaneous | 2 | 1993 | 58 | 0.040 |
Why?
|
| Skin Pigmentation | 2 | 1988 | 40 | 0.040 |
Why?
|
| Photochemistry | 2 | 2001 | 38 | 0.040 |
Why?
|
| Dermatology | 1 | 1996 | 35 | 0.040 |
Why?
|
| Extremities | 1 | 2017 | 167 | 0.030 |
Why?
|
| Pemphigoid, Bullous | 1 | 1996 | 12 | 0.030 |
Why?
|
| Sunscreening Agents | 1 | 2015 | 7 | 0.030 |
Why?
|
| Paraneoplastic Syndromes | 1 | 1995 | 16 | 0.030 |
Why?
|
| Neoplasm Transplantation | 3 | 2002 | 391 | 0.030 |
Why?
|
| Sunburn | 1 | 2015 | 8 | 0.030 |
Why?
|
| Pregnancy Complications, Neoplastic | 1 | 1995 | 28 | 0.030 |
Why?
|
| Pyoderma Gangrenosum | 1 | 1995 | 19 | 0.030 |
Why?
|
| Patch Tests | 1 | 1995 | 4 | 0.030 |
Why?
|
| Survival Rate | 2 | 2002 | 1863 | 0.030 |
Why?
|
| Biomarkers, Tumor | 1 | 2003 | 1464 | 0.030 |
Why?
|
| Child | 4 | 1996 | 6928 | 0.030 |
Why?
|
| Erythrocytes | 3 | 1990 | 255 | 0.030 |
Why?
|
| Receptors, Cell Surface | 2 | 1986 | 286 | 0.030 |
Why?
|
| Deoxyribodipyrimidine Photo-Lyase | 1 | 1993 | 1 | 0.030 |
Why?
|
| Pyrimidine Dimers | 1 | 1993 | 4 | 0.030 |
Why?
|
| Fibroblasts | 2 | 1994 | 729 | 0.030 |
Why?
|
| Dose-Response Relationship, Drug | 4 | 2002 | 1961 | 0.030 |
Why?
|
| Dermatitis, Phototoxic | 1 | 1993 | 2 | 0.030 |
Why?
|
| Oxygen Consumption | 2 | 2006 | 239 | 0.030 |
Why?
|
| Calcium | 1 | 1998 | 1156 | 0.030 |
Why?
|
| Tumor Stem Cell Assay | 1 | 1993 | 35 | 0.030 |
Why?
|
| Phosphotransferases | 1 | 1993 | 65 | 0.030 |
Why?
|
| Thymidine | 1 | 1993 | 59 | 0.030 |
Why?
|
| Metabolic Clearance Rate | 1 | 1993 | 121 | 0.030 |
Why?
|
| Darkness | 1 | 1993 | 49 | 0.030 |
Why?
|
| Glycine | 1 | 1993 | 92 | 0.030 |
Why?
|
| Gene Amplification | 1 | 1993 | 131 | 0.030 |
Why?
|
| Methylprednisolone | 2 | 1995 | 66 | 0.030 |
Why?
|
| Skin Tests | 2 | 1993 | 44 | 0.030 |
Why?
|
| Oxygen | 2 | 2012 | 726 | 0.030 |
Why?
|
| Plant Proteins | 1 | 1993 | 132 | 0.030 |
Why?
|
| Drug Resistance | 1 | 1993 | 256 | 0.030 |
Why?
|
| Amino Acid Substitution | 1 | 2013 | 339 | 0.030 |
Why?
|
| Antibodies, Monoclonal | 1 | 2018 | 1376 | 0.030 |
Why?
|
| Mutation, Missense | 1 | 2013 | 276 | 0.030 |
Why?
|
| Child, Preschool | 2 | 2010 | 3613 | 0.020 |
Why?
|
| DNA Repair | 1 | 1993 | 356 | 0.020 |
Why?
|
| Physical Examination | 1 | 1992 | 149 | 0.020 |
Why?
|
| Incidence | 1 | 2015 | 1577 | 0.020 |
Why?
|
| Patient Satisfaction | 1 | 2014 | 455 | 0.020 |
Why?
|
| Differential Threshold | 1 | 1990 | 12 | 0.020 |
Why?
|
| Superoxides | 1 | 1990 | 73 | 0.020 |
Why?
|
| Cell Line, Tumor | 2 | 2006 | 2426 | 0.020 |
Why?
|
| Rejuvenation | 1 | 2010 | 18 | 0.020 |
Why?
|
| Radiation-Protective Agents | 1 | 1990 | 96 | 0.020 |
Why?
|
| Microscopy | 1 | 2010 | 87 | 0.020 |
Why?
|
| Radiation Injuries | 2 | 1989 | 155 | 0.020 |
Why?
|
| Lupus Erythematosus, Systemic | 1 | 1992 | 206 | 0.020 |
Why?
|
| Organometallic Compounds | 1 | 1990 | 132 | 0.020 |
Why?
|
| Gangliosides | 2 | 1986 | 10 | 0.020 |
Why?
|
| Amiodarone | 1 | 1989 | 12 | 0.020 |
Why?
|
| Pigmentation Disorders | 1 | 1989 | 13 | 0.020 |
Why?
|
| Leukemia, Myeloid, Acute | 1 | 1995 | 763 | 0.020 |
Why?
|
| In Vitro Techniques | 1 | 1990 | 989 | 0.020 |
Why?
|
| Up-Regulation | 2 | 2006 | 712 | 0.020 |
Why?
|
| Antineoplastic Agents | 1 | 2000 | 2360 | 0.020 |
Why?
|
| Lymphocytes | 1 | 1990 | 464 | 0.020 |
Why?
|
| Clinical Trials as Topic | 3 | 1988 | 1169 | 0.020 |
Why?
|
| Neoplasm Staging | 1 | 1994 | 1939 | 0.020 |
Why?
|
| Drug Combinations | 1 | 1989 | 224 | 0.020 |
Why?
|
| Facial Neoplasms | 1 | 1987 | 25 | 0.020 |
Why?
|
| Necrosis | 1 | 1987 | 204 | 0.020 |
Why?
|
| Rats, Inbred Strains | 2 | 2003 | 312 | 0.020 |
Why?
|
| Cyclophosphamide | 1 | 1987 | 299 | 0.020 |
Why?
|
| Coproporphyrinogen Oxidase | 1 | 2006 | 1 | 0.020 |
Why?
|
| Tetrazolium Salts | 1 | 2006 | 11 | 0.020 |
Why?
|
| Drug Therapy, Combination | 1 | 1989 | 894 | 0.020 |
Why?
|
| Pyrimidinones | 1 | 2006 | 36 | 0.020 |
Why?
|
| Trioxsalen | 1 | 1986 | 2 | 0.020 |
Why?
|
| Eyelids | 1 | 1986 | 23 | 0.020 |
Why?
|
| Alanine Transaminase | 1 | 1986 | 73 | 0.020 |
Why?
|
| Aspartate Aminotransferases | 1 | 1986 | 73 | 0.020 |
Why?
|
| Thiazoles | 1 | 2006 | 131 | 0.020 |
Why?
|
| Melanocytes | 1 | 1986 | 56 | 0.020 |
Why?
|
| Chemical and Drug Induced Liver Injury | 1 | 1986 | 69 | 0.020 |
Why?
|
| Seasons | 1 | 1986 | 223 | 0.020 |
Why?
|
| Amino Acids | 2 | 1997 | 252 | 0.020 |
Why?
|
| 3-Phosphoshikimate 1-Carboxyvinyltransferase | 2 | 1994 | 2 | 0.020 |
Why?
|
| Lymphoma | 1 | 1986 | 262 | 0.020 |
Why?
|
| Immunohistochemistry | 1 | 1988 | 1753 | 0.020 |
Why?
|
| Chloroplasts | 2 | 1994 | 68 | 0.010 |
Why?
|
| Liver Diseases | 1 | 1986 | 238 | 0.010 |
Why?
|
| Phenotype | 1 | 2010 | 2378 | 0.010 |
Why?
|
| Neoplasm Metastasis | 1 | 1987 | 1056 | 0.010 |
Why?
|
| Matrix Metalloproteinase 2 | 1 | 2003 | 44 | 0.010 |
Why?
|
| Matrix Metalloproteinases | 1 | 2002 | 28 | 0.010 |
Why?
|
| Papanicolaou Test | 1 | 2002 | 38 | 0.010 |
Why?
|
| Vaginal Smears | 1 | 2002 | 68 | 0.010 |
Why?
|
| Polylysine | 1 | 2001 | 33 | 0.010 |
Why?
|
| Subcellular Fractions | 1 | 2001 | 93 | 0.010 |
Why?
|
| Cell Proliferation | 1 | 2006 | 1578 | 0.010 |
Why?
|
| Pregnancy | 2 | 1999 | 2894 | 0.010 |
Why?
|
| Xenograft Model Antitumor Assays | 1 | 2001 | 458 | 0.010 |
Why?
|
| Ventilation | 1 | 1999 | 7 | 0.010 |
Why?
|
| Skin Temperature | 1 | 1999 | 14 | 0.010 |
Why?
|
| Sodium Azide | 1 | 1999 | 5 | 0.010 |
Why?
|
| Deuterium Oxide | 1 | 1999 | 10 | 0.010 |
Why?
|
| Catalase | 1 | 1999 | 48 | 0.010 |
Why?
|
| Hematoporphyrins | 1 | 1999 | 1 | 0.010 |
Why?
|
| Models, Biological | 1 | 2006 | 1749 | 0.010 |
Why?
|
| Molecular Sequence Data | 2 | 1994 | 3030 | 0.010 |
Why?
|
| Arsenic | 2 | 1996 | 251 | 0.010 |
Why?
|
| Lysosomes | 1 | 1999 | 104 | 0.010 |
Why?
|
| Disease Progression | 1 | 2003 | 1531 | 0.010 |
Why?
|
| Spectrometry, Mass, Secondary Ion | 1 | 1997 | 2 | 0.010 |
Why?
|
| Pregnancy Complications, Infectious | 1 | 1999 | 105 | 0.010 |
Why?
|
| Cell Adhesion | 1 | 1999 | 420 | 0.010 |
Why?
|
| Oxylipins | 1 | 1997 | 16 | 0.010 |
Why?
|
| Gas Chromatography-Mass Spectrometry | 1 | 1997 | 40 | 0.010 |
Why?
|
| Stereoisomerism | 1 | 1997 | 102 | 0.010 |
Why?
|
| Plant Leaves | 1 | 1997 | 72 | 0.010 |
Why?
|
| Dihematoporphyrin Ether | 1 | 1996 | 4 | 0.010 |
Why?
|
| Membrane Proteins | 1 | 1984 | 1196 | 0.010 |
Why?
|
| Metalloporphyrins | 1 | 1996 | 26 | 0.010 |
Why?
|
| Sarcoma, Kaposi | 1 | 1996 | 19 | 0.010 |
Why?
|
| Molecular Structure | 1 | 1997 | 287 | 0.010 |
Why?
|
| Administration, Topical | 1 | 1996 | 95 | 0.010 |
Why?
|
| Structure-Activity Relationship | 1 | 1997 | 408 | 0.010 |
Why?
|
| Biomarkers | 1 | 2003 | 1718 | 0.010 |
Why?
|
| Tars | 1 | 1996 | 1 | 0.010 |
Why?
|
| Fluorescent Antibody Technique, Direct | 1 | 1996 | 10 | 0.010 |
Why?
|
| Cocarcinogenesis | 1 | 1996 | 12 | 0.010 |
Why?
|
| Retinoids | 1 | 1996 | 17 | 0.010 |
Why?
|
| Fluorescent Antibody Technique, Indirect | 1 | 1996 | 68 | 0.010 |
Why?
|
| Complement C3 | 1 | 1996 | 58 | 0.010 |
Why?
|
| Chronic Disease | 1 | 1999 | 971 | 0.010 |
Why?
|
| Dapsone | 1 | 1995 | 10 | 0.010 |
Why?
|
| X-Rays | 1 | 1996 | 130 | 0.010 |
Why?
|
| Rosette Formation | 2 | 1986 | 34 | 0.010 |
Why?
|
| Keratosis | 1 | 1995 | 21 | 0.010 |
Why?
|
| Basement Membrane | 1 | 1996 | 54 | 0.010 |
Why?
|
| Immunoglobulin M | 1 | 1996 | 154 | 0.010 |
Why?
|
| Pregnancy Trimester, Second | 1 | 1995 | 66 | 0.010 |
Why?
|
| Epidermis | 1 | 1996 | 100 | 0.010 |
Why?
|
| Switzerland | 1 | 1995 | 17 | 0.010 |
Why?
|
| Austria | 1 | 1995 | 19 | 0.010 |
Why?
|
| Immunoblotting | 1 | 1996 | 268 | 0.010 |
Why?
|
| Germany | 1 | 1995 | 72 | 0.010 |
Why?
|
| Disease Models, Animal | 1 | 2002 | 2232 | 0.010 |
Why?
|
| RNA, Plant | 1 | 1994 | 20 | 0.010 |
Why?
|
| Radiation Dosage | 1 | 1996 | 227 | 0.010 |
Why?
|
| Ferrochelatase | 1 | 1994 | 1 | 0.010 |
Why?
|
| Cyclosporine | 1 | 1995 | 234 | 0.010 |
Why?
|
| Autoantibodies | 1 | 1996 | 267 | 0.010 |
Why?
|
| Cytosol | 1 | 1994 | 189 | 0.010 |
Why?
|
| Skin Transplantation | 1 | 1995 | 172 | 0.010 |
Why?
|
| Verapamil | 1 | 1994 | 48 | 0.010 |
Why?
|
| Spectrometry, Fluorescence | 1 | 1994 | 85 | 0.010 |
Why?
|
| Regression Analysis | 1 | 1996 | 596 | 0.010 |
Why?
|
| Allergens | 1 | 1995 | 179 | 0.010 |
Why?
|
| Biological Transport | 1 | 1994 | 396 | 0.010 |
Why?
|
| Opossums | 1 | 1993 | 4 | 0.010 |
Why?
|
| Oligonucleotide Probes | 1 | 1993 | 39 | 0.010 |
Why?
|
| Enzyme Induction | 1 | 1993 | 88 | 0.010 |
Why?
|
| Risk Factors | 2 | 1996 | 5417 | 0.010 |
Why?
|
| Electrophoresis, Polyacrylamide Gel | 1 | 1993 | 268 | 0.010 |
Why?
|
| Carcinoma, Transitional Cell | 1 | 1994 | 164 | 0.010 |
Why?
|
| Species Specificity | 1 | 1993 | 678 | 0.010 |
Why?
|
| DNA Damage | 1 | 1993 | 366 | 0.010 |
Why?
|
| Amino Acid Sequence | 1 | 1994 | 2062 | 0.010 |
Why?
|
| Adaptation, Physiological | 1 | 1993 | 306 | 0.010 |
Why?
|
| Urinary Bladder Neoplasms | 1 | 1994 | 383 | 0.010 |
Why?
|
| Base Sequence | 1 | 1993 | 2330 | 0.010 |
Why?
|
| Microscopy, Electron | 1 | 1989 | 503 | 0.010 |
Why?
|
| Face | 1 | 1989 | 114 | 0.010 |
Why?
|
| Furocoumarins | 1 | 1988 | 2 | 0.010 |
Why?
|
| Chemistry | 1 | 1988 | 54 | 0.010 |
Why?
|
| Chemical Phenomena | 1 | 1988 | 72 | 0.010 |
Why?
|
| Mesocricetus | 1 | 1988 | 107 | 0.010 |
Why?
|
| Yeasts | 1 | 1988 | 49 | 0.010 |
Why?
|
| Cross-Linking Reagents | 1 | 1988 | 86 | 0.000 |
Why?
|
| Biological Availability | 1 | 1988 | 92 | 0.000 |
Why?
|
| Diagnosis, Differential | 1 | 1992 | 1565 | 0.000 |
Why?
|
| Random Allocation | 1 | 1988 | 332 | 0.000 |
Why?
|
| Genes | 1 | 1988 | 305 | 0.000 |
Why?
|
| Cricetinae | 1 | 1988 | 560 | 0.000 |
Why?
|
| Etretinate | 1 | 1986 | 4 | 0.000 |
Why?
|
| Dose-Response Relationship, Immunologic | 1 | 1986 | 42 | 0.000 |
Why?
|
| Binding, Competitive | 1 | 1986 | 145 | 0.000 |
Why?
|
| Carbohydrates | 1 | 1986 | 47 | 0.000 |
Why?
|
| Sialic Acids | 1 | 1984 | 18 | 0.000 |
Why?
|
| Neuraminic Acids | 1 | 1984 | 10 | 0.000 |
Why?
|
| Cycloheximide | 1 | 1984 | 56 | 0.000 |
Why?
|
| Trypsin | 1 | 1984 | 95 | 0.000 |
Why?
|
| Lactose | 1 | 1984 | 27 | 0.000 |
Why?
|
| Breast Neoplasms | 1 | 1996 | 2903 | 0.000 |
Why?
|
| Retrospective Studies | 1 | 1996 | 8491 | 0.000 |
Why?
|
| Mutation | 1 | 1993 | 3968 | 0.000 |
Why?
|
| Aging | 1 | 1986 | 691 | 0.000 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 1986 | 1313 | 0.000 |
Why?
|
| T-Lymphocytes | 1 | 1986 | 1195 | 0.000 |
Why?
|